Adaptimmune Therapeutics (NASDAQ:ADAP) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Adaptimmune Therapeutics (NASDAQ:ADAP) posted its earnings results on Monday. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.

Adaptimmune Therapeutics Stock Performance

Shares of NASDAQ ADAP traded down $0.01 during mid-day trading on Monday, reaching $0.28. 2,891,945 shares of the company’s stock were exchanged, compared to its average volume of 1,687,464. The firm has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.26 and a beta of 2.52. The firm has a 50-day moving average price of $0.54 and a two-hundred day moving average price of $0.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 52 week low of $0.26 and a 52 week high of $1.65.

Analysts Set New Price Targets

Several brokerages have recently commented on ADAP. Wells Fargo & Company lowered their price objective on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday. Scotiabank lowered their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday. They issued a “buy” rating for the company. Finally, Mizuho dropped their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $2.18.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.